Halozyme Therapeutics, Inc.

NasdaqGS:HALO Stock Report

Market Cap: US$5.7b

Halozyme Therapeutics Valuation

Is HALO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HALO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HALO ($45.76) is trading below our estimate of fair value ($164.28)

Significantly Below Fair Value: HALO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HALO?

Key metric: As HALO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HALO. This is calculated by dividing HALO's market cap by their current earnings.
What is HALO's PE Ratio?
PE Ratio14.8x
EarningsUS$392.47m
Market CapUS$5.70b

Price to Earnings Ratio vs Peers

How does HALO's PE Ratio compare to its peers?

The above table shows the PE ratio for HALO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.6x
ROIV Roivant Sciences
1.8x-46.3%US$8.2b
SRPT Sarepta Therapeutics
86.9x42.6%US$10.2b
NBIX Neurocrine Biosciences
32.3x29.6%US$12.1b
EXEL Exelixis
21.2x15.6%US$9.8b
HALO Halozyme Therapeutics
14.8x21.1%US$5.7b

Price-To-Earnings vs Peers: HALO is good value based on its Price-To-Earnings Ratio (14.8x) compared to the peer average (35.6x).

Price to Earnings Ratio vs Industry

How does HALO's PE Ratio compare vs other companies in the US Biotechs Industry?

11 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ROIV Roivant Sciences
1.8x-46.3%US$8.23b
AGIO Agios Pharmaceuticals
4.6x-56.7%US$3.10b
INBX Inhibrx Biosciences
0.1xn/aUS$206.86m
CTMX CytomX Therapeutics
4.9x-35.8%US$69.86m
HALO 14.8xIndustry Avg. 16.8xNo. of Companies11PE020406080100+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HALO is good value based on its Price-To-Earnings Ratio (14.8x) compared to the US Biotechs industry average (17.2x).

Price to Earnings Ratio vs Fair Ratio

What is HALO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HALO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.8x
Fair PE Ratio27.5x

Price-To-Earnings vs Fair Ratio: HALO is good value based on its Price-To-Earnings Ratio (14.8x) compared to the estimated Fair Price-To-Earnings Ratio (27.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HALO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$45.76
US$62.44
+36.5%
14.2%US$75.00US$50.00n/a9
Nov ’25US$57.15
US$62.50
+9.4%
13.7%US$75.00US$50.00n/a10
Oct ’25US$56.64
US$61.10
+7.9%
13.5%US$75.00US$48.00n/a10
Sep ’25US$63.85
US$59.10
-7.4%
12.1%US$72.00US$48.00n/a10
Aug ’25US$55.05
US$57.90
+5.2%
11.3%US$72.00US$49.00n/a10
Jul ’25US$52.02
US$57.40
+10.3%
12.8%US$72.00US$44.00n/a10
Jun ’25US$44.29
US$51.30
+15.8%
15.6%US$71.00US$41.00n/a10
May ’25US$39.30
US$50.50
+28.5%
17.1%US$72.00US$39.00n/a11
Apr ’25US$41.32
US$50.70
+22.7%
17.8%US$72.00US$39.00n/a10
Mar ’25US$41.11
US$48.64
+18.3%
22.2%US$72.00US$28.00n/a11
Feb ’25US$34.26
US$47.50
+38.6%
23.9%US$72.00US$28.00n/a10
Jan ’25US$36.96
US$50.30
+36.1%
22.4%US$72.00US$28.00n/a10
Dec ’24US$39.69
US$51.27
+29.2%
21.5%US$72.00US$28.00n/a11
Nov ’24US$33.51
US$51.27
+53.0%
21.6%US$72.00US$28.00US$57.1511
Oct ’24US$38.20
US$51.80
+35.6%
21.9%US$72.00US$28.00US$56.6410
Sep ’24US$42.82
US$51.80
+21.0%
21.9%US$72.00US$28.00US$63.8510
Aug ’24US$42.28
US$50.60
+19.7%
24.1%US$72.00US$26.00US$55.0510
Jul ’24US$36.07
US$48.56
+34.6%
23.2%US$66.00US$26.00US$52.029
Jun ’24US$32.49
US$49.60
+52.7%
21.3%US$66.00US$26.00US$44.2910
May ’24US$32.63
US$52.40
+60.6%
23.1%US$68.00US$26.00US$39.3010
Apr ’24US$38.19
US$52.70
+38.0%
23.1%US$68.00US$26.00US$41.3210
Mar ’24US$47.62
US$56.22
+18.1%
22.6%US$68.00US$26.00US$41.119
Feb ’24US$52.17
US$56.22
+7.8%
22.0%US$68.00US$26.00US$34.269
Jan ’24US$56.90
US$56.00
-1.6%
23.7%US$68.00US$23.00US$36.969
Dec ’23US$57.40
US$53.22
-7.3%
22.5%US$65.00US$23.00US$39.699
Nov ’23US$48.28
US$48.00
-0.6%
24.2%US$59.00US$21.00US$33.517

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%